Physician profile
Casey L Sharp
NPI 1063961472
$62,813.87
in general payments reported to CMS, 2019-2025
37 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,072 · 2022: $1,633 · 2023: $14K · 2024: $19K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Food and Beverage: $4,712 · Travel and Lodging: $219 · Education: $3.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,175.00 |
| Food and Beverage | $4,711.87 |
| Travel and Lodging | $219.10 |
| Education | $3.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $57,043.61 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $835.94 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $666.92 | 2022-2024 | Ingrezza |
| Alkermes, INC. | $465.53 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $418.77 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $387.75 | 2021-2024 | Qelbree, Qelbree |
| Novo Nordisk INC | $357.70 | 2021-2023 | Rybelsus, Ozempic |
| Abbott Laboratories | $333.19 | 2021-2023 | Freestyle Libre 3 |
| Corium, LLC | $270.14 | 2023-2024 | Azstarys |
| Lilly USA, LLC | $228.05 | 2021-2024 | Zepbound, Mounjaro, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $205.52 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $177.67 | 2022-2024 | Auvelity |
| Amgen INC. | $168.40 | 2021-2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $167.84 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Biohaven Pharmaceuticals, INC. | $108.55 | 2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Sharp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.